C. Louvet

Institute Mutualiste Montsouris — France

Medicine · Health Sciences

14h-index1.0kcitations94works3.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(38), Cancer Treatment and Pharmacology(26), Gastric Cancer Management and Outcomes(23), Pancreatic and Hepatic Oncology Research(16), Cancer Genomics and Diagnostics(14)

Publications94 total

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
Communications Medicine·2025· 5 citedOpen Access
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)
Journal of Clinical Oncology·2025· 17 cited
Prognostic Value Of Circulating Tumor DNA At Diagnosis And Its Early Decrease After One Cycle Of Neoadjuvant Chemotherapy For Patients With Advanced Epithelial Ovarian Cancer. An Ancillary Analysis Of The Randomized CHIVA Phase II GINECO.
International Journal of Gynecological Cancer·2025
Prognostic value of tumor regression grade (TRG) in patients with gastric/gastroesophageal junction cancer treated by peri-operative chemotherapy and surgery: A single-center experience (Institut Mutualiste Montsouris, Paris, France).
Journal of Clinical Oncology·2025
The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors
Journal of Neuro-Oncology·2025· 4 citedOpen Access
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Gynecologic Oncology·2024· 3 citedOpen Access
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
2024Open Access
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Molecular Cancer·2024· 10 citedOpen Access
Valeur pronostique de la cinétique précoce de l’ADN tumoral circulant en cours de chimiothérapie néoadjuvante pour les patientes présentant un cancer épithélial de l’ovaire à un stade avancé. Résultats préliminaires d’une analyse ancillaire de l’étude de phase II CHIVA (ARCAGY-GINECO)
Gynécologie Obstétrique Fertilité & Sénologie ·2024
Early Clinical and Molecular Biomarkers in Advanced Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: Chiva Phase Ii Gineco Trial
SSRN Electronic Journal·2024Open Access
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
Annals of Oncology·2022· 39 citedOpen Access
1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO
2021Open Access
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
Annals of Oncology·2020· 151 citedOpen Access
Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial
International Journal of Radiation Oncology*Biology*Physics·2017
Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study
European Journal of Cancer·2016
Évolution de l’orbitopathie basedowienne après traitement par iode131 administré pour un cancer différencié de la thyroïde
Annales d Endocrinologie·2016
Infundibulo-neuro-hypophysite dans le cadre d’un syndrome de Gougerot-Sjögren primaire, traitée avec succès par le mycophénolate mofétil
Annales d Endocrinologie·2015
2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)
European Journal of Cancer·2015
Center impact on survival in metastatic colorectal cancer trials.
Journal of Clinical Oncology·2011
Interest of systematic patient contact by phone call between two cycles of chemotherapy.
Journal of Clinical Oncology·2011
page 1 of 5Next →

Frequent Co-authors

Thierry André(20), Armand de Gramont(12), M Krulik(11), Gérard Lledo(8), Benoist Chibaudel(8), Jacques Balosso(6), Aimery de Gramont(6), C. Varette(6), Pascal Hammel(6), de Gramont A(6), May Mabro(5), B Demuynck(5), Christophe Tournigand(5), Laurent Mineur(4), F. Maindrault-Gœbel(4), Pascal Artru(4), Michel Ducreux(4), Franck Bonnetain(4), Éric Raymond(3), Julien Taı̈eb(3)